[TABLE OF CONTENTS TO ANNUAL REPORT ON FORM 10-K FOR YEAR ENDED MARCH 31, 2016 Page PART I. Item 1. Business. 1 Item 1A. Risk Factors. 15 Item 1B. Unresolved Staff Comments. 33 Item 2. Properties. 34 Item 3. Legal Proceedings. 34 Item 4. Mine Safety Disclosures. 34 PART II. Item 5. 35 Item 6. Selected Financial Data. 35 Item] [List of Subsidiaries 1. Renovation Investment (Hong Kong) Co., Ltd. (“Renovation”) is a Hong Kong company and is wholly-owned by the Company. 2. Hangzhou Jiutong Medical Technology Co., Ltd. (“Jiutong Medical”) is a Chinese company and is wholly-owned by Renovation. 3. Zhejiang Shouantang Pharmaceutical Technology Co., Ltd. (“Shouantang Technology”) is a Chinese company and is wholly-owned by Renovation. 4. Zhejiang] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM BDO CHINA SHU LUN PAN Certified Public Accountants LLP June 28, 2016 EX-23.1 3 f10k2016ex23i_chinajojodrug.htm CONSENT OF INDEPENDENT PUBLICLY REGISTERED ACCOUNTING FIRM, BDO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lei Liu, certify that: (1) I have reviewed this annual report on Form 10-K of China Jo-Jo Drugstores, Inc.; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ming Zhao, certify that: (1) I have reviewed this annual report on Form 10-K of China Jo-Jo Drugstores, Inc.; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Lei Liu Chief Executive Officer Ming Zhao Chief Financial Officer (Principal Financial and Accounting Officer) June 28,]

[China Jo-Jo Drugstores Announces the Fourth Quarter and Year End Financial Results for Fiscal Year 2016 Q4 Gross Profit grew 29.0%, EPS increased to $0.05/share FY 2016 Revenue up 15.8%, Online Pharmacy Sales Increased 77.8% HANGZHOU, China, June 28, 2016 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ CM: CJJD) (the "Company" or "China Jo-Jo"), a leading China-based pharmacy with retail,] []